<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04771247</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00277820</org_study_id>
    <nct_id>NCT04771247</nct_id>
  </id_info>
  <brief_title>Endoscopic Cardiac Band Ligation for the Management of Refractory GERD After Laparoscopic Sleeve Gastrectomy</brief_title>
  <acronym>CLEAR</acronym>
  <official_title>Endoscopic Cardiac Band Ligation (CLEAR) Without Sleeve Stenosis for the Management of Refractory GERD After Laparoscopic Sleeve Gastrectomy (LSG)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Johns Hopkins University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      GERD is a prevalent condition worldwide, estimated to be around 20-30 % in North America.&#xD;
      Obesity is rapidly increasing with an estimated prevalence of 66% in the adult population in&#xD;
      the United States. Presently, bariatric interventions are the only sustainable method to&#xD;
      address morbid obesity and its resulting comorbidities. One of the most common restrictive&#xD;
      surgeries includes laparoscopic sleeve gastrectomy (LSG). Although very effective for&#xD;
      treating obesity, some of these surgeries might cause deleterious effects regarding GERD, due&#xD;
      to anatomical modifications. Refractory GERD is defined by lack of symptom control on maximum&#xD;
      dose of PPI therapy. Cardia Band Ligation Anti-reflux (CLEAR) procedure utilizes multiple&#xD;
      band ligations at the cardia in a 270-degree fashion, resulting in tissue necrosis and scar&#xD;
      formation, narrowing the GE junction and enhancing the flap valve system. The investigators&#xD;
      hypothesized that CLEAR can be a safe and efficient intervention to improve post bariatric&#xD;
      GERD.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      GERD is a prevalent condition worldwide, estimated to be around 20-30 % in North America.&#xD;
      Obesity is rapidly increasing with an estimated prevalence of 66% in the adult population in&#xD;
      the United States. GERD symptoms are common in the obese population with data showing weekly&#xD;
      GERD symptoms in 34.6% and erosive esophagitis 26.9% in people with BMI &gt; 30 Kg/m^2. Reflux&#xD;
      is associated with complications such as esophagitis, Barrett's Esophagus and ultimately&#xD;
      esophageal adenocarcinoma. Presently, bariatric interventions are the only sustainable method&#xD;
      to address morbid obesity and its resulting comorbidities. There are endoscopic and surgical&#xD;
      bariatric interventions. Bariatric surgery has been shown to be an effective and efficient&#xD;
      means of achieving significant weight loss in obese individuals. One of the most common&#xD;
      restrictive surgeries includes laparoscopic sleeve gastrectomy (LSG). Although very effective&#xD;
      for treating obesity, some of these surgeries might cause deleterious effects regarding GERD,&#xD;
      due to anatomical modifications. LSG can increase the incidence of GERD, which may be&#xD;
      explained from the changes in the angle of His and by increasing intragastric pressure.&#xD;
      Pharmacological therapy with proton pump inhibitors (PPI), H2 blockers and lifestyle changes&#xD;
      are first line forms of treatment utilized to control the symptoms related to GERD. However,&#xD;
      patients who use pharmacological treatment experience reduction in quality of life and seek&#xD;
      alternative options. Refractory GERD is defined by lack of symptom control on maximum dose of&#xD;
      PPI therapy. Moreover, due to the anatomical changes associated with bariatric surgeries, the&#xD;
      traditional surgical and endoscopic techniques (TIF, Nissen Fundoplication) used to treat&#xD;
      GERD in the general population are not suitable for these patients. With the current trend of&#xD;
      an increase of bariatric surgery and thus GERD that arises after these surgeries, new&#xD;
      innovative techniques to treat GERD are needed, especially in PPI averse or non-responsive&#xD;
      patients. Cardia Band Ligation Anti-reflux (CLEAR) procedure utilizes multiple band ligations&#xD;
      at the cardia in a 270-degree fashion, resulting in tissue necrosis and scar formation,&#xD;
      narrowing the GE junction and enhancing the flap valve system. The investigators will perform&#xD;
      CLEAR by placing 4 bands at the GEJ. The investigators hypothesized that CLEAR can be a safe&#xD;
      and efficient intervention to improve post bariatric GERD.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    IRB approval withheld&#xD;
  </why_stopped>
  <start_date type="Anticipated">September 2021</start_date>
  <completion_date type="Anticipated">September 2021</completion_date>
  <primary_completion_date type="Anticipated">September 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Prospective, single center, pilot clinical trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in GERD-HQRL/RSI score</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>Change in symptoms assessed by GERD-HQRL/RSI score at 6 months.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in pH monitoring</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>Change in objective pH monitoring at 6 months.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean change on the percentage of acid exposure time (% AET)</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>Changes in acid exposure time from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety of CLEAR procedure as assessed by treatment-related adverse events</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Assess overall safety (treatment-related adverse events) of CLEAR procedure defined by the ASGE-Lexicon classification.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of dysphagia post CLEAR</measure>
    <time_frame>6-12 months</time_frame>
    <description>Percentage of patients who develop dysphagia of any grade, associated with esophageal or gastric cardia stricture requiring dilation after CLEAR procedure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PPI discontinuation</measure>
    <time_frame>6 months</time_frame>
    <description>Percentage of patients who no longer require PPI at 6 months post CLEAR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PPI discontinuation</measure>
    <time_frame>12 months</time_frame>
    <description>Percentage of patients who no longer require PPI at 12 months post CLEAR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment failure</measure>
    <time_frame>6 months</time_frame>
    <description>Defined as less than 50% improvement in GERD HQRL/RSI score or pH monitoring.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>GERD</condition>
  <condition>Bariatric Surgery</condition>
  <condition>Laparoscopic Sleeve Gastrectomy</condition>
  <arm_group>
    <arm_group_label>CLEAR</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with GERD post LSG will undergo CLEAR (cardia band ligation).</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Cardia Band Ligation</intervention_name>
    <description>Patients will undergo cardia band ligation at the level of the GEJ.</description>
    <arm_group_label>CLEAR</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Obese patients who underwent surgical bariatric weight loss procedures with&#xD;
             post-surgical GERD (LSG), not responding to once daily PPI therapy.&#xD;
&#xD;
          -  Obese patients who underwent surgical bariatric weight loss procedures with&#xD;
             post-surgical GERD (LSG) who respond to maximum therapy with PPI + H2 blocker but are&#xD;
             PPI averse or who refuse surgical therapy (conversion to RYGBP).&#xD;
&#xD;
          -  Patients older than 18 years and younger than 75 years of age at time of consent.&#xD;
&#xD;
          -  Patients able to provide written informed consent on the IRB/EC-approved informed&#xD;
             consent form&#xD;
&#xD;
          -  Patients willing and able to comply with study requirements for follow-up&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any patient with no prior surgical bariatric intervention.&#xD;
&#xD;
          -  Pre-existing esophageal stenosis/stricture preventing advancement of an endoscope&#xD;
             during screening/baseline EGD.&#xD;
&#xD;
          -  Esophageal, gastric or duodenal malignancy.&#xD;
&#xD;
          -  Severe medical comorbidities precluding endoscopy, or limiting life expectancy to less&#xD;
             than 2 years in the judgment of the endoscopist.&#xD;
&#xD;
          -  Uncontrolled coagulopathy or inability to be off anticoagulation or anti-platelet&#xD;
             medication (ASA, Plavix) for 1 week prior to and 2 weeks after each endoscopy&#xD;
&#xD;
          -  Active fungal esophagitis, Grade C or D esophagitis.&#xD;
&#xD;
          -  Hiatal hernias &gt; 2 cm or para-esophageal hernias.&#xD;
&#xD;
          -  Known portal hypertension, visible esophageal or gastric varices, or history of&#xD;
             esophageal varices.&#xD;
&#xD;
          -  General poor health, multiple co-morbidities placing the patient at risk, or otherwise&#xD;
             unsuitable for trial participation.&#xD;
&#xD;
          -  Pregnant or planning to become pregnant during period of study participation.&#xD;
&#xD;
          -  Patient refuses or is unable to provide written informed consent.&#xD;
&#xD;
          -  Prior surgical or endoscopic anti-reflux procedure.&#xD;
&#xD;
          -  Persistent dysphagia score greater than 0.&#xD;
&#xD;
          -  Vomiting more than once a week.&#xD;
&#xD;
          -  Biopsy-proven Barrett's esophagus.&#xD;
&#xD;
          -  HREM showing marked ineffective esophageal motility (defined by â‰¥ 5 weak or failed&#xD;
             swallows per Chicago Classification v 3.0), esophagogastric outflow obstruction&#xD;
             (EGJOO) or achalasia.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Olaya I Brewer Gutierrez</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <reference>
    <citation>Seleem WM, Hanafy AS, Mohamed SI. Endoscopic management of refractory gastroesophageal reflux disease. Scand J Gastroenterol. 2018 Apr;53(4):390-397. doi: 10.1080/00365521.2018.1445775. Epub 2018 Feb 28.</citation>
    <PMID>29488430</PMID>
  </reference>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>February 23, 2021</study_first_submitted>
  <study_first_submitted_qc>February 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 25, 2021</study_first_posted>
  <last_update_submitted>September 22, 2021</last_update_submitted>
  <last_update_submitted_qc>September 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CLEAR</keyword>
  <keyword>Antireflux procedure</keyword>
  <keyword>LSG</keyword>
  <keyword>GERD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastroesophageal Reflux</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

